TTFields, Taxol Combo Shows Promise in Recurrent Ovarian Cancer Patients

TTFields, Taxol Combo Shows Promise in Recurrent Ovarian Cancer Patients
Patients with recurrent ovarian cancer may greatly benefit from the addition of Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel), according to recent data from the pilot INNOVATE trial. Recent data presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C., has shown that the combination more than doubled patients' median progression-free survival (PFS) compared to historical controls receiving Taxol alone. The study was titled "INNOVATE: a phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma." “A clear unmet need remains for patients with recurrent ovarian cancer, particularly in the platinum-resistant population, with median overall survival of only 13 to 14 months post recurrence,” Dr. Igance Vergote, chair of the Department of Obstetrics and Gynecology at Catholic University Leuven in Belgium, said in a press release. “These data show that treatment with TTFields has the potential to make a difference in the lives of recurrent ovarian cancer patients.” Novocure's TTFields is a noninvasive, regional treatment modality that is currently approved by the U.S. Food and Drug Administration to treat patients with newly diagnosed glioblastoma, an aggressive type of brain cancer. It acts by delivering intermediate
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *